Drug intelligence / Profile preview

NOVO-113

Development stage: Unknown
Lead developer: InnovoTEX
Modality: Small Molecules

Overview

NOVO-113 is an investigational macrocycle drug conjugate (MDC) designed as a targeted therapy that delivers a poly(ADP-ribose) polymerase (PARP) inhibitor payload. Developed by InnovoTEX, the candidate is designed to inhibit PARP-mediated DNA damage repair (DDR) pathways, selectively targeting tumor cells to exploit synthetic lethality while minimizing systemic toxicity. NOVO-113 is currently in the discovery stage of development for undisclosed solid tumor indications.

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on NOVO-113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NOVO-113.